title: [Clinical investigation of oral high-dose medroxyprogesterone acetate (MPA) in advanced breast cancer--double-blind controlled study: Japanese Group for MPA Treatment of Breast Cancer].
abstract: A randomized controlled trial was made to compare the therapeutic result of oral high-dose medroxyprogesterone acetate (HD-MPA) versus mepitiostane (MS) in the treatment of postmenopausal breast cancer. MPA (1200 mg) was given p.o., b.i.d. to 47 patients and produced objective response in 19 of them (40.4%). Objective response was seen in 14 of the 40 control patients given MS p.o., b.i.d. (35.0%). Among patients with bone metastases, 6/19 (31.6%) for HD-MPA and 2/23 (15.4%) for MS showed objective response. The other merits of HD-MPA suggested in the study were improvement in performance status, anabolic effect and myeloprotective effect.
authors.forename: M
authors.initials: M
authors.lastname: Izuo
authors.forename: T
authors.initials: T
authors.lastname: Tominaga
authors.forename: M
authors.initials: M
authors.lastname: Yoshida
authors.forename: Y
authors.initials: Y
authors.lastname: Nomura
authors.forename: O
authors.initials: O
authors.lastname: Abe
authors.forename: K
authors.initials: K
authors.lastname: Enomoto
authors.forename: K
authors.initials: K
authors.lastname: Kubo
authors.forename: O
authors.initials: O
authors.lastname: Takatani
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000732:Androstanols / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002214:Capsules; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D017258:Medroxyprogesterone Acetate; D008875:Middle Aged
chemical_list: D000732:Androstanols; D000970:Antineoplastic Agents; D002214:Capsules; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone; C006242:mepitiostane